Home
About
Capabilities
R&D
Investors
News
Careers
中文
Home
About
Capabilities
R & D
Investors
News
Careers
Press Release
Press Release
2025
2024
2023
2022
2021
2020
2019
2018
2017
Mar 06, 2024
Mabwell to Present the Clinical Data of 9MW2821 in Cervical Cancer as Focused Plenary Oral Presentation at 2024 Society of Gynecologic Oncology Annual Meeting on Women's Cancer
➞
Feb 25, 2024
FDA Grants Fast Track Designation to 9MW2821
➞
Feb 19, 2024
Mabwell Publishes the Phase III Study Results on Its Denosumab Biosimilar (MW032) in the journal JAMA Oncology
➞
Feb 18, 2024
FDA Grants Orphan Drug Designation to 9MW3011
➞
Feb 18, 2024
Mabwell Receives IND Approval from FDA for Novel B7-H3 ADC 7MW3711
➞
Jan 31, 2024
Mabwell and Fudan University Shanghai Cancer Center Renew Strategic Cooperation Agreement
➞
Jan 04, 2024
Mabwell Established a Licensing and Commercialization Agreement for MAILISHU Indonesia Market
➞
Jan 02, 2024
Mabwell to attend 42nd JP Morgan Healthcare Conference and present at Biotech Showcase
➞
Previous
1
2
3
4